Analyst Price Targets — GRCE
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 24, 2026 1:26 pm | — | Craig-Hallum | $4.00 | $2.18 | TheFly | Grace Therapeutics price target lowered to $4 from $11 at Craig-Hallum |
Latest News for GRCE
Grace Therapeutics Inc. (NASDAQ:GRCE) shares are down during Friday's premarket session following a regulatory update regarding its New Drug Application (NDA) for GTx-104.
Grace Therapeutics said on Thursday the U.S. Food and Drug Administration declined to approve its drug for a rare type of stroke.
FDA Issued Complete Response Letter Citing Outstanding Items Related to Chemistry, Manufacturing, and Controls and Non-Clinical Information
PRINCETON, N.J., April 14, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for intravenous infusion to address significant unmet medical needs in aneurysmal subarachnoid hemorrhage (aSAH) patients, today announced that an abstract…
Grace Therapeutics, Inc. (NASDAQ: GRCE - Get Free Report) was the recipient of a significant increase in short interest in March. As of March 13th, there was short interest totaling 1,565,407 shares, an increase of 300.8% from the February 26th total of 390,568 shares. Approximately 11.4% of the company's stock are sold short. Based on an
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for GRCE.
U.S. House Trading
No House trades found for GRCE.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.